Citations

Clear

158 citation(s) found for "Hartman, A-R".

Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis.
Oxnard, Geoffrey R. , Chen, Xiaoji , Fung, Eric T. , Ma, Ting , Lipson, Jafi A. , Patel, Shilpen, Shaknovich, Rita , Brooks, Jacqueline D., Seiden, Michael V., Aravanis, Alex, Hartman, Anne‐Renee , Liu, Minetta C. , Hubbell, Earl , Kurtzman, Kathryn N. , Zhao, Dong , Liu, Hai , Spigel, David R. , Aravanis, Alexander M. , Klein, Eric A.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 1545-1545

10.1200/jco.2019.37.15_suppl.1545 Get It

1545 Background: Screening tests for early cancer detection are often criticized due to risk of overdiagnosis—detection of good prognosis cancers which may not require immediate treatment. We recently reported development of cfDNA sequencing approaches for cancer detection; longitudinal follow-up (F/U) data were utilized here to evaluate prognostic significance of cancer detection using cfDNA. Methods: Plasma cfDNA samples were subjected to whole-genome bisulfite sequencing (WGBS, 30X) as part of a previously-reported Circulating Cell-free Genome Atlas (CCGA; NCT02889978) substudy. This exploratory analysis evaluated the overall survival (OS) of training and test set participants (pts) with cancer (20 cancer types, any stage I-IV). Combining train and test set pts, univariate and multivariate analyses (Cox proportional hazards) assessed OS association with WGBS result (cancer detected vs not detected, set at 98% specificity), clinical stage (IV vs I-III), diagnostic method (symptom- vs screen-detected), sex, age, and histologic grade. Results: Of 827 pts from the training set with F/U (median 12.2 mo), 334 (40.4%) had WGBS-detected cancer. Among 127 (15.4%) pts with cancer that died during F/U, cancer was detected in 104 (81.9%). Results were similar in the test set. In univariate analyses all variables were associated with prognosis, including WGBS result (HR 7.7 p<0.001). In multivariate analyses accounting for other covariates, the three variables that most significantly remained prognostic were WGBS (HR 3.0, p<0.001), clinical stage (HR 3.3, p<0.001), and diagnostic method (HR 3.0, p<0.001). Validation of these findings is ongoing in an independent cohort of ~5,000 cancer pts from CCGA using an optimized assay; updated performance results will be reported. Conclusions: Cancers detected using WGBS of cfDNA had a worse prognosis than cancers not detected. WGBS cancer detection carried comparable prognostic significance as clinical stage. By preferentially detecting higher risk cancers, cancer detection using plasma cfDNA may avoid some of the overdiagnosis that has been seen with some existing cancer screening methods. Clinical trial information: NCT02889978.
Reply to “Supporting Family Physician Maternity Care Providers”
Goldstein, Jessica Taylor , Hartman, Scott, Meunier, Matthew R. , Panchal, Bethany, Pecci, Christine Chang , Zink, Nancy M., Shields, Sara G.

Mayo Clinic

Family Medicine | May 10, 2019 | Volume: 51 | Issue: 5 | Pages: 447-447

10.22454/fammed.2019.119002 | PMID 31081923 Get It

Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors.
Wilcoxen, Keith, Becker, Marc A., Neff, Christopher, Abkevich, Victor, Jones, Joshua T., Hou, Xiaonan , Wang, Yan , Hartman, Anne‐Renee , AlHilli, Mariam , Gutin, Alexander , Agarwal, Shefali , Timms, Kirsten M. , Neff, Chris, Haluska, Paul

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5532-5532

10.1200/jco.2015.33.15_suppl.5532 Get It

Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery
Gruber, Lucinda , Hartman, Robert P. , Thompson, Geoffrey B. , McKenzie, Travis J. , Lyden, Melanie L. , Dy, Benzon M. , Gruber, Lucinda M, Young, William F. , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 19, 2018 | Volume: 104 | Issue: 5 | Pages: 1386-1393

10.1210/jc.2018-01707 | PMID 30462226 Get It

Idiopathic CD4 Lymphocytopenia with Fulminant Pneumocystis jirovecii Pneumonia
Jundt, Michael C., Ayalew, Assefa M., Hartman, Thomas E. , Roden, Anja C. , Koo, Chi Wan

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 15, 2018 | Volume: 199 | Issue: 8 | Pages: e35-e36

10.1164/rccm.201802-0267im | PMID 30321488 Get It

Supporting Family Physician Maternity Care Providers
Goldstein, Jessica Taylor , Hartman, Scott, Meunier, Matthew R. , Panchal, Bethany, Pecci, Christine Chang , Zink, Nancy M., Shields, Sara G.

Mayo Clinic

Family Medicine | October 2, 2018 | Volume: 50 | Issue: 9 | Pages: 662-671

10.22454/fammed.2018.325322 | PMID 30307583 Get It

Maternity care access in the United States is in crisis. The American Congress of Obstetrics and Gynecology projects that by 2030 there will be a nationwide shortage of 9,000 obstetrician-gynecologists (OB/GYNs). Midwives and OB/GYNs have been called upon to address this crisis, yet in underserved areas, family physicians are often providing a majority of this care. Family medicine maternity care, a natural fit for the discipline, has been on sharp decline in recent years for many reasons including difficulties cultivating interdisciplinary relationships, navigating privileging, developing and maintaining adequate volume/competency, and preventing burnout. In 2016 and 2017, workshops were held among family medicine educators with resultant recommendations for essential strategies to support family physician maternity care providers. This article summarizes these strategies, provides guidance, and highlights the role family physicians have in addressing maternity care access for the underserved as well as presenting innovative ideas to train and retain rural family physician maternity care providers.
Genetic heterogeneity and survival among pancreatic adenocarcinoma (PDAC) patients with positive family history.
Petersen, Gloria M. , Chaffee, Kari G. , Majithia, Neil , Allen, Brian, Singh, Nanda, Hartman, Anne‐Renee , Oberg, Ann L. , McWilliams, Robert R. , Kidd, John

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4108-4108

10.1200/jco.2016.34.15_suppl.4108 Get It

Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.
Maddala, Tara, Aravanis, Alex, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Venn, Oliver, Yeatman, Timothy J. , Tibshirani, Robert , Williams, Richard T. , Hartman, Anne‐Renee , Seiden, Michael V., Liu, Minetta C. , Klein, Eric A. , Hubbell, Earl , Aravanis, Alexander M. , Gross, Samuel, Kurtzman, Kathryn N. , Zhang, Nan , Smith, David A. B.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 12021-12021

10.1200/jco.2018.36.15_suppl.12021 Get It